What are the risks associated with combined antiplatelet-warfarin therapy after coronary stenting?
According to the studies referenced in the context, the main risks associated with combined antiplatelet-warfarin therapy after coronary stenting include an increased risk of bleeding due to the antithrombotic therapy, as well as a risk of stroke and other thromboembolic complications due to a decrease in the efficacy of the anticoagulant medication.